Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Account Payables: 2014-2024

Historic Change in Account Payables for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to -$2.9 million.

  • Cartesian Therapeutics' Change in Account Payables rose 173.67% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 1531.48%. This contributed to the annual value of -$2.9 million for FY2024, which is 203.28% down from last year.
  • Cartesian Therapeutics' Change in Account Payables amounted to -$2.9 million in FY2024, which was down 203.28% from $2.8 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Change in Account Payables registered a high of $2.8 million during FY2023, and its lowest value of -$2.9 million during FY2024.
  • Its 3-year average for Change in Account Payables is -$333.33, with a median of $92,000 in 2022.
  • Its Change in Account Payables has fluctuated over the past 5 years, first slumped by 284.21% in 2021, then skyrocketed by 2,980.43% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' Change in Account Payables (Yearly) stood at -$57,000 in 2020, then tumbled by 284.21% to -$219,000 in 2021, then soared by 142.01% to $92,000 in 2022, then spiked by 2,980.43% to $2.8 million in 2023, then tumbled by 203.28% to -$2.9 million in 2024.